Item 7.01 Regulation FD Disclosure.
Beginning on March 8, 2022, members of management of VYNE Therapeutics Inc. (the
"Company") will begin using the updated investor presentation found on the
Company's website in connection with investor meetings and industry conferences.
The presentation has been updated to include the preclinical data for the
Company's lead BET inhibitor, VYN201, in a human skin model of vitiligo, as
announced by the Company on March 7, 2022. In addition, the presentation
reflects an updated timeline for the Company's receipt of top line results from
its Phase 2a study evaluating the safety and efficacy of FMX114 for the
treatment of mild-to-moderate atopic dermatitis. The Company expects to report
Phase 2a top line results in the second quarter of 2022, versus prior
expectations of the first quarter 2022, primarily due to COVID-19-related
enrollment delays in Australia, where the study is being conducted. The updated
investor presentation can be found in the "Events & Presentations" section of
the Company's website.
The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to
the liabilities of that Section, or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing.
© Edgar Online, source Glimpses